CV Sciences, Inc. Receives Nutritional Outlook’s 2018 Best of the Industry Award
Company’s industry-dominating hemp extract brand, PlusCBD Oil™ wins Best Retail/Brand Product category
LAS VEGAS, Dec. 12, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our” or “we”), preeminent supplier and manufacturer of hemp-derived phytocannabinoids including cannabidiol (CBD) oil and developer of specialty pharmaceutical therapeutics, announced today that it has received Nutritional Outlook’s 2018 Best of the Industry Awards, Retail/Brand Product, for the Company’s best-selling PlusCBD Oil™ line of hemp-derived CBD products.
Editor-in-Chief Jennifer Grebow states, “In Nutritional Outlook's 2018 Best of the Industry Awards, we are recognizing individuals, groups, and companies whose initiatives today may help shape, for the better, the state of the dietary supplement and food and beverage industries for years to come.”
CV Sciences was recognized for its leadership role in providing transparency to the safety of its ingredients, which include hemp extract comprising of a full spectrum of naturally-occurring phytocannabinoids including CBD, fatty acids, terpenes, plant sterols and vitamin E. In September 2018, the Company’s Gold Formula products received self-affirmed Generally Recognized as Safe (GRAS) status in accordance with U.S. Food and Drug Administration (FDA) safety guidelines, an initiative demonstrating its dedication in establishing responsible practices for the burgeoning hemp CBD industry.
“Nutritional Outlook has been on the forefront of the nutraceutical industry, providing news and insight to over 200,000 industry professionals,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “We are pleased to be honored amongst fellow industry stalwarts for our commitment to building consumer confidence and trust in the safety and quality of our products.
Nutritional Outlook is a leading resource for manufacturers of dietary supplements and healthy food and beverages. The publication adheres to the highest standards of editorial quality, providing nutraceuticals professionals with the information they need and trust to grow their companies.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products (PlusCBD Oil™) to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California; and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
Investor and Media Contact:
Released December 12, 2018